



Frank Misselwitz, MD PhD

Frank Misselwitz is currently Vice President of Global Clinical Development and Head of the Cardiovascular Therapeutic Area at Bayer HealthCare AG, Wuppertal, Germany, where he has worked for nine years.

After receiving his MD and an MSc in medical biophysics in 1981, Dr Misselwitz earned his PhD in 1984. His interest in thrombosis was first evident in his doctoral thesis on cellular biology of atherosclerosis and thrombosis. He has worked in the thrombosis field for over 20 years, initially as an active physician and director of the Haemostasis Laboratory at the Institute for

Cardiovascular Research of the Academy of Sciences in Berlin, and later at various pharmaceutical companies.

He has been responsible for the worldwide clinical development of rivaroxaban since 2002. He was involved in the planning and execution of the phase II clinical studies, and is currently heavily involved in the planning and execution of the phase III studies. In 2005 he became Vice President and Head of the Therapeutic Area Cardiovascular and Coagulation.

Dr Misselwitz is the author of over 200 scientific publications in highly respected journals, and is a member of several international societies, including the American Society of Hematology and the American Heart Association.